![Eric Hughes](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Vermögen: 4 Mio $ am 31.05.2026
Dr. Eric A. Hughes is an Independent Director at Monte Rosa Therapeutics, Inc. and a Chief Medical Officer, Executive VP-Global R&D at Teva Pharmaceutical Industries Ltd. He is on the Board of Directors at Monte Rosa Therapeutics, Inc. Dr. Hughes was previously employed as a SVP-Clinical Development & Translational Medicine by Vertex Pharmaceuticals, Inc. He received his graduate degree from Yale School of Medicine and a doctorate degree from Yale School of Medicine.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 20.03.2026 | 107’711 ( 0.01% ) | 4 Mio $ | 31.05.2026 | |
| 11.06.2026 | 0 ( -.--% ) | - $ | 31.05.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| TEVA PHARMACEUTICAL INDUSTRIES LIMITED | Technik-/Wissenschafts-/F&E-Leiter | 01.08.2022 |
| MONTE ROSA THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 13.12.2024 |
| Unternehmen | Position | Ende |
|---|---|---|
| VERTEX PHARMACEUTICALS INCORPORATED | Corporate Officer/Principal | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 4 |
|---|---|
Vertex Pharmaceuticals, Inc.
 Vertex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company that develops drugs for the treatment of cystic fibrosis | Health Technology |
Teva Pharmaceutical Industries Ltd.
 Teva Pharmaceutical Industries Ltd. Pharmaceuticals: GenericHealth Technology Manufactures and markets generic and proprietary branded pharmaceuticals and active pharmaceutical ingredients | Health Technology |
Yale School of Medicine
 Yale School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Monte Rosa Therapeutics, Inc.
 Monte Rosa Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that develops molecular glue degrader medicines for oncology, autoimmune and inflammatory diseases | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen
